Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BERYL DRUGS vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BERYL DRUGS   MYLAN
EQUITY SHARE DATA
    BERYL DRUGS
Mar-23
MYLAN
Dec-18
BERYL DRUGS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs183,974-   
Low Rs82,187-   
Sales per share (Unadj.) Rs53.01,828.4-  
Earnings per share (Unadj.) Rs1.549.6-  
Cash flow per share (Unadj.) Rs3.1392.0-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs15.91,978.0-  
Shares outstanding (eoy) m5.07514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.21.7 14.3%   
Avg P/E ratio x8.462.0 13.6%  
P/CF ratio (eoy) x4.17.9 52.1%  
Price / Book Value ratio x0.81.6 51.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m651,584,872 0.0%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m150-   
Avg. sales/employee Rs Th026,878.2-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0729.9-  
INCOME DATA
Net Sales Rs m269940,736 0.0%  
Other income Rs m30-   
Total revenues Rs m272940,736 0.0%   
Gross profit Rs m20243,428 0.0%  
Depreciation Rs m8176,143 0.0%   
Interest Rs m545,246 0.0%   
Profit before tax Rs m1022,039 0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2-3,506 -0.1%   
Profit after tax Rs m825,545 0.0%  
Gross profit margin %7.425.9 28.6%  
Effective tax rate %22.1-15.9 -139.2%   
Net profit margin %2.82.7 104.9%  
BALANCE SHEET DATA
Current assets Rs m104525,306 0.0%   
Current liabilities Rs m64383,006 0.0%   
Net working cap to sales %14.815.1 98.0%  
Current ratio x1.61.4 118.2%  
Inventory Days Days1484 16.9%  
Debtors Days Days93793 1,003.8%  
Net fixed assets Rs m71182,487 0.0%   
Share capital Rs m51501 10.2%   
"Free" reserves Rs m300-   
Net worth Rs m811,017,705 0.0%   
Long term debt Rs m271,098,430 0.0%   
Total assets Rs m1752,729,879 0.0%  
Interest coverage x3.11.5 208.9%   
Debt to equity ratio x0.31.1 31.2%  
Sales to assets ratio x1.50.3 446.4%   
Return on assets %7.12.6 271.9%  
Return on equity %9.52.5 378.3%  
Return on capital %13.43.2 422.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m25195,485 0.0%  
From Investments Rs m-13-101,044 0.0%  
From Financial Activity Rs m-12-91,068 0.0%  
Net Cashflow Rs m01,620 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.48 Rs / USD

Compare BERYL DRUGS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare BERYL DRUGS With: AMI ORGANICS  THEMIS MEDICARE  ISTREET NETWORK  WINDLAS BIOTECH  BLISS GVS PHARMA  



Today's Market

Sensex Today Ends 384 Points Lower | Realty Index Down 4%| Marico Rallies 9% Sensex Today Ends 384 Points Lower | Realty Index Down 4%| Marico Rallies 9%(Closing)

After opening the day flat, Indian share markets turned negative as the session progressed and ended lower.